BioPharmSignal logoBioPharmSignal

Biotech News

Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights

Biomea Fusion (BMEA)Biomea FusionEarnings

Enrollment ongoing for the Phase II COVALENT-211 clinical trial in patients with insulin deficiency in Type 2 diabetes (“T2D”); data expected in the first quarter of 2027 Enrollment also ongoing for the Phase II COVALENT-212 clinical trial in patients with T2D not achieving glycemic targets while

Related news

BMEABiomea Fusion2026-06-05 23:32 EST

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study

BMEABiomea Fusion2026-06-03 12:00 EST

Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity

RLAYRelay Therapeutics2026-07-30 20:05 EST

Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026

LYELLyell Immunopharma2026-08-06 20:05 EST

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026

GERNGeron2026-08-05 11:00 EST

Geron Corporation Reports Second Quarter 2026 Financial Results and Recent Business Highlights

RLAYRelay Therapeutics2026-08-06 20:05 EST

Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates

CMPXCompass Therapeutics2026-08-06 11:30 EST

Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update

CGEMCullinan Therapeutics, Inc.2026-08-06 11:00 EST

Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

EXELExelixis2026-08-05 20:05 EST

Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update

RVMDRevolution Medicines2026-08-05 20:02 EST

Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress

View all latest news

Biomea Fusion

Metabolic Disease Company Biomea Fusion develops small molecules intended to restore metabolic function in diabetes and obesity. Icovamenib Icovamenib is a covalent menin inhibitor being evaluated for potential restoration of insulin-producing beta-cell function in type 1 and type 2 diabetes. COVALENT Program COVALENT-211 and...

Recent company news

BMEABiomea Fusion2026-08-05 20:05 EST

Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights

BMEABiomea Fusion2026-06-05 23:32 EST

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study

BMEABiomea Fusion2026-06-03 12:00 EST

Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity

BMEABiomea Fusion2026-05-12 20:05 EST

Biomea Fusion to Participate at Upcoming Investor Conferences

BMEABiomea Fusion2026-05-11 20:55 EST

Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights

Stock data

Close
1.25 USD
Market cap
99.05M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States